Dovarizumab is an injection that is given primarily by intravenous infusion, and this medication should not be used for more than 12 months at the longest. The recommended dose of Duvariyumab is usually 10 mg per kilogram of body weight, and each infusion should not last less than one hour, usually twice a week. This drug is mainly indicated for the treatment of patients with unresectable stage III non-small cell lung cancer who have not experienced disease progression after receiving platinum-based chemotherapy with concurrent radiotherapy. This drug is more toxic during use, such as liver injury, kidney injury, etc. In the process of using this drug, you need to closely observe the adverse reactions, and the risks and benefits of using this drug are assessed by your doctor, and you need to use it with caution under the guidance of your doctor.